CEO Raha Samraat S. buys 40,000 shares of MYGN at $5.00; holds 493.1K shares (+8.8%) as stock down -54.3% from 52-week high.
Raha Samraat S., President and CEO, purchased 40,000 shares at $5.00 on 2026-03-09, increasing his holdings from 453.1K to 493.1K shares. This transaction occurred while MYRIAD GENETICS trades -54.3% below its 52-week high of $10.52 and the company faces material headwinds: net income of $-27.4M on quarterly revenue of $205.7M, annual revenue contraction of -1.6%, and unprofitability over the most recent full fiscal year. The purchase itself is discrete, but it arrives against a backdrop of sustained stock deterioration (-34.6% over 90 days, -6.0% over 30 days) and operational distress. The absolute price level ($5.00) and the magnitude of acquisition (8.8% increase to CEO holdings) merit investor attention to understand management's confidence thesis in a period of both market decline and negative earnings.